Dupixent Sales Soar 30.8%, Beating Estimates in Sanofi's Q1 Report
REGN sits 57% above its 52-week low of $476.487.
Summary
Sanofi reported first-quarter earnings that edged past estimates, significantly boosted by strong demand for its blockbuster drug Dupixent. Sales of Dupixent, developed in partnership with Regeneron, surged 30.8% at constant exchange rates to 4.17 billion euros ($4.88 billion), comfortably beating analyst expectations of 3.89 billion euros. This positive sales performance for Dupixent follows recent EU and FDA approvals for the drug in new indications, reinforcing its robust growth trajectory. The better-than-expected sales are a significant positive indicator for Regeneron, as Dupixent is a key revenue driver for the company. Investors will monitor future sales trends for Dupixent and Regeneron's own upcoming earnings report for further details on its share of the revenue.
At the time of this announcement, REGN was trading at $745.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.9B. The 52-week trading range was $476.49 to $821.11. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.